Literature DB >> 10650316

Potent complementary clinical benefit of abciximab and stenting during percutaneous coronary revascularization in patients with diabetes mellitus: results of the EPISTENT trial.

A M Lincoff1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10650316     DOI： 10.1067/mhj.2000.103743

Source DB:  PubMed          Journal:  Am Heart J        ISSN： 0002-8703            Impact factor:   4.749


× No keyword cloud information.
  3 in total

Review 1.  Antiplatelet agents for chronic kidney disease.

Authors:  Patrizia Natale; Suetonia C Palmer; Valeria M Saglimbene; Marinella Ruospo; Mona Razavian; Jonathan C Craig; Meg J Jardine; Angela C Webster; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2022-02-28

Review 2.  Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation.

Authors:  Tim Ibbotson; Jane K McGavin; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Effect of a dual drug-coated stent with abciximab and alpha-lipoic Acid in a porcine coronary restenosis model.

Authors:  Kyung Seob Lim; Young Joon Hong; Daisuke Hachinohe; Khurshid Ahmed; Myung Ho Jeong; Jung Ha Kim; Doo Sun Sim; Min Goo Lee; Keun-Ho Park; Ju Han Kim; Youngkeun Ahn; Jeong Gwan Cho; Jong Chun Park; Sun-Jung Song; Kyoung Woon Jung; Dong Lyun Cho; Jung Chaee Kang
Journal:  Korean Circ J       Date:  2011-05-31       Impact factor: 3.243
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.